Acute Respiratory Distress Syndrome Treatment Market Size, Share and Global Trend By Drug Class (Vasoconstrictors, Bronchodilators, Steroids and Antibiotics, Nitric Oxide, Sedatives & Paralytics, Surfactant), By Route of Administration (Oral, Injection, Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2024-2032

Acute respiratory distress syndrome (ARDS) refers to a medical condition in which the lungs are not able to take up an adequate amount of oxygen and supply to other vital organs. It occurs due to the accumulation of fluids in alveoli, preventing the lungs from filling up enough amount of air due to which less oxygen reaches the bloodstream. Acute respiratory distress syndrome often results from another underlying cause such as sepsis, severe pneumonia, inhalation of harmful substances, head, chest, or another major injury.

The symptoms of acute respiratory distress syndrome include low blood pressure, severe shortness of breath, unusually rapid breathing, confusion and extreme tiredness, and others. The cases of acute respiratory distress syndrome among infants are gradually increasing. The common treatment methods for acute respiratory distress syndrome is through mechanical ventilation, IV fluids, inhaled medications such as nitric oxide, surfactants, and others.

To gain extensive insights into the market, Request for Customization

Increase in investment in research by both government and private organization have led to a huge upsurge in global acute respiratory distress syndrome treatment market. For example, HEALIOS K.K, a company focussed on developing cellular and regeneration medicines, acquired the development and commercialization rights of MultiStem, a stem cell product under clinical study for acute respiratory distress syndrome, which is anticipated to accelerate the global acute respiratory distress syndrome treatment market growth.

Global acute respiratory distress syndrome treatment market growth is being driven by the emerging guidelines for the management of acute respiratory distress syndrome, potential pipeline products, and rise in a number of neonatal intensive care units. Furthermore, increased research on stem cell and strategic collaborations to develop treatment of acute respiratory distress syndrome are further expected to fuel the global acute respiratory distress syndrome treatment market growth in the forecast period.

However, the presence of limited approved medicines for the treatment of acute respiratory distress syndrome and prominent use of mechanical ventilation devices are factors that can inhibit the growth in global acute respiratory distress syndrome treatment market.

Key Players Covered

The major companies covered in the global acute respiratory distress syndrome treatment market report include Athersys Inc., mondoBIOTECH AG, HEALIOS K.K., GlaxoSmithKline plc., Pfizer Inc., Teva Pharmaceuticals USA Inc., Altor BioScience, Faron Pharmaceuticals, Ltd., and other players.

SEGMENTATION

As per the current acute respiratory distress syndrome treatment market trends, steroids and antibiotics among the drug class segment are anticipated to register a higher market share in the global acute respiratory distress syndrome treatment market owing to the common usage in acute respiratory distress syndrome treatment.

Key Insights

• Epidemiology of Acute Respiratory Distress Syndrome for Key Countries


• Applied SWOT Analysis


• PESTLE Analysis


• Pipeline Analysis


• Guideline for Management of Acute Respiratory Distress Syndrome


• Overview of Inhalation Devices: Acute Respiratory Distress Syndrome


• Key Mergers and Acquisitions

Regional Analysis

The acute respiratory distress syndrome treatment market is expected to have an exponential growth in North America by the end of 2025 owing to the increased research for the development of new therapy and emerging guidelines for the management of patients with acute respiratory distress syndrome. Altor BioScience, a biopharmaceutical company, is researching an antibody-based tissue factor (TF) antagonist namely ALT-836 for the treatment of infection-induced acute respiratory distress syndrome, which is projected to favor acute respiratory distress syndrome treatment market in North America. In Europe and the Asia Pacific, the acute respiratory distress syndrome treatment market is anticipated to expand due to the increasing prevalence of acute respiratory distress syndrome and a rising number of intensive care units. Additionally, acute respiratory distress syndrome treatment market in Latin America & the Middle East and Africa is in the nascent stage; however, unmet needs for treatment is expected to drive the market growth in this region.

Acute Respiratory Distress Syndrome Treatment Industry Developments

• In May 2019, Athersys Inc. announced the fast track designation from the U.S. FDA for the MultiStem Program for the treatment of acute respiratory distress syndrome


• In January 2018, Faron Pharmaceuticals, Ltd. announced that the U.S. FDA granted an Investigational New Drug (IND) application for traumakine, for the treatment of acute respiratory distress syndrome